EUCTR2012-005138-12-ES进行中（未招募）1 期
Randomized phase II study of treatment with R-CHOP vs Bortezomib-R-CAP for young patients with poor IPI diffuse large B-cell lymphoma.
GELTAMO (Grupo Cooperativo Español de Linfoma/Trasplante Autólogo de Médula Ósea)0 个研究点目标入组 127 人开始时间: 2013年1月9日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 127
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.- Patients diagnosed with primary diffuse DLBCL who have never received treatment for this condition.
- •2.- Age between 18 and 70 years.
- •3.- Age adjusted IPI higher than 1 or equal 1, with high levels of beta-2-microglobulin (above UNL)
- •4.- Neoplasic B lymphocytes for CD20 positivity.
- •5.- ECOG 0-3
- •6.- More than 12 weeks of life expectancy.
- •7.- Signed Informed Consent.
- •8.- Nor pregnant women nor breast-feeding women without heterosexual activity during the entire study. Women with heterosexual activity only if they are willing to use two methods of contraceptive. The two contraceptive methods can be, two barrier method or a barrier method combinated with an hormonal contraceptive method to prevent pregnancy, used during the entire study and until 3 months after the study completion.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 127
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 127
排除标准
- •1. Pregnant women or in breast-feeding period, or adults in childbearing period not using an effective contraception method.
- •2. Patients with CNS lymphoma
- •3. Patients with severe impairment of renal function (creatinine> 2.5 UNL) or hepatic (bilirubin or ALT / AST> 3 UNL), unless it is suspected to be due to the disease.
- •4. HIV positive patients
- •5. Patient previously treated for the DLBCL
- •6. Positive determination of chronic hepatitis B (defined as positive serology for HBsAg). It will be allowed to enroll patients with hidden or previuos hepatitis (defined as positive antibodies against the core of the hepatitis B virus [HBcAb] and HBsAg negative) if undetectable HBV DNA.
- •7. Positive results for hepatitis C (antibody serology for hepatitis C virus [HCV]). Patients with HCV positive may participate only if the result of the PCR is negative for HCV RNA.
- •8.Patients with previous history of cardiac disease: ventricular ejection fraction < 50%.
- •9. Patients with severe psiquiatric conditions that may interfere with their ability to understand the study (including alcoholism or drug addiction).
- •10. Patients with known hypersensitivity to murine proteins or any other component of the study drugs.
- •11. Transformed follicular lymphoma.
- •12. History of other primary malignancy with < 5 year of complete response (except for basal or squamous cell carcinomas of the skin or cervical carcinoma in situ).
- •13. Uncontrolled current illness: cardiac, pulmonary, neurologic, metabolic etc, not related to lymphoma.
- •14. Uncontrolled hypertension (diastolic blood pressure over 110 mmHg).
- •15. Psychiatric illnesses that could compromise the patient participation in the study.
- •16. Known or suspected hypersensitivity to any of the agents of the study.
研究者
相似试验
进行中（未招募）
不适用
An Open-label, Randomized, Phase 2 Study of R-CHOP Plus Enzastaurin versus R-CHOP in the First-Line Treatment of Patients with Intermediate and High-Risk Diffuse Large B-Cell Lymphoma - N/AFirst-Line Diffuse Large B-Cell LymphomaMedDRA version: 9.1Level: LLTClassification code 10012855Term: Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation)EUCTR2008-005496-10-IEEli Lilly and Company100
已完成
2 期
Randomized phase II/III study of R-CHOP versus weekly rituximab plus CHOP for CD20 positive diffuse large B cell lymphoma (JCOG0601)CD20 positive diffuse large B cell lmyphomaJPRN-UMIN000000929Japan Clinical Oncology Group(JCOG)422
已完成
2 期
Randomized phase II study of biweekly R-CHOP versus biweekly R-CHOP followed by CHASER as induction therapy for high-dose chemotherapy, LEED, and autologous stem-cell transplantation in poor-risk diffuse large B-cell lymphoma (JCOG0908, DLBCL-bi-R-CHOP/CHASER-LEED-rP2 )diffuse large B-cell lymphoma, including subtypeslymphomatoid granulomatosis, grade 3primary mediastinal (thymic) large B-cell lymphomaJPRN-UMIN000003823Japan Clinical Oncology Group (JCOG)70
进行中（未招募）
1 期
A Parallel Randomised Phase II Trial of CHOP Chemotherapy With or Without Bortezomib in Relapsed Mantle Cell Lymphoma - Bortezomib StudyRelapsed, or refractory mantle cell lymphomaMedDRA version: 20.0 Level: PT Classification code 10026800 Term: Mantle cell lymphoma recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2006-006090-24-GBPlymouth Hospitals NHS Trust46
进行中（未招募）
1 期
A trial of CHOP-R therapy with or without acalabrutinib in patients with newly diagnosed Richter's SyndromeEUCTR2017-004401-40-GBniversity of Birmingham105